Protease inhibitor-based triple therapy in chronic hepatitis C: Guidelines by the French Association for the Study of the Liver

Liver International

Volumn 32, Issue 10, 2012, Pages 1477-1492

  Leroy, Vincent ^a   Serfaty, Lawrence ^b   Bourlière, Marc ^c   Bronowicki, Jean Pierre ^d   Delasalle, Patrick ^e   Pariente, Alexandre ^f   Pol, Stanislas ^g   Zoulim, Fabien ^h   Pageaux, Georges Philippe ⁱ  

^a INSTITUT ALBERT BONNIOT   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c HÔPITAL SAINT JOSEPH   (France)

^d UNIVERSITY HOSPITAL OF NANCY   (France)

^e Cabinet d'hépato gastroentérologie   (France)

^f Service d'hépato gastroentérologie Hôpital   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h UNIVERSITÉ LYON 1   (France)

ⁱ HÔPITAL SAINT ELOI   (France)

Author keywords

Boceprevir; Cirrhosis; Fibrosis; IL28B; Telaprevir

Indexed keywords

ANTIARRHYTHMIC AGENT; BENZODIAZEPINE; BOCEPREVIR; CISAPRIDE; DEXAMETHASONE; ERGOT DERIVATIVE; ERYTHROPOIETIN; HYPERICUM PERFORATUM EXTRACT; ITRACONAZOLE; KETOCONAZOLE; MACROLIDE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PHENOBARBITAL; PHENYTOIN; POSACONAZOLE; PROTEINASE INHIBITOR; RIBAVIRIN; RIFABUTIN; RIFAMPICIN; SILDENAFIL; TELAPREVIR; VIRUS RNA;

ANEMIA; ANTIVIRAL RESISTANCE; CLINICAL PRACTICE; DRESS SYNDROME; DRUG EFFICACY; DRUG INDICATION; DRUG TREATMENT FAILURE; ECZEMA; FOOD DRUG INTERACTION; GRAPEFRUIT; HEPATITIS C; HUMAN; HYPERPIGMENTATION; LICHEN PLANUS; LIVER CIRRHOSIS; LIVER FIBROSIS; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREDICTION; PRURIGO; PRURITUS; REVIEW; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; XEROSIS;

ANTIVIRAL AGENTS; DRUG COMBINATIONS; FRANCE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; PROTEASE INHIBITORS; RIBAVIRIN; TIME FACTORS;

EID: 84867097569     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2012.02856.x     Document Type: Review

References (41)

1. Meffre C, Le Strat Y, Delarocque-Astagneau E, et al. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol 2010; 82: 546-55.
2. Deuffic-Burban S, Mathurin P, Pol S, et al. The availability of direct acting antivirals in 2012: a French model based analysis of the increased number of patients treated for chronic HCV infection. Gut 2012; 61: 290-6.
3. Deuffic-Burban S, Deltenre P, Buti M, et al. HCV burden in Europe: impact of national treatment practices on future HCV-related morbidity and mortality through a modeling approach. J Hepatol 2011; 54: S54.
4. Conférence de consensus. Traitement de l'hépatite C. Gastroenterol Clin Biol 2002; 26: B303-20.
5. Craxi A. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264.
6. Fartoux L, Chazouilleres O, Wendum D, et al. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 2005; 41: 82-7.
7. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-93.
8. Bourlière M, Ouzan D, Rosenheim M, et al. Peg interferon alfa-2a plus ribavirin for chronic hepatitis C in a real life setting: the Hepatys French cohort (2003-2007). Antiviral Ther 2011; 2012(17): 101-10.
9. Shiffman ML, Morishima C, Dienstag JL, et al. Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology 2009; 137: 1986-94.
10. Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Inter Med 2008; 149: 399-403.
11. Saadoun D, Delluc A, Piette JC, et al. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr Opin Rheumatol 2008; 20: 23-8.
12. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
13. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-9.
14. Moreno C, Deltenre P, Pawlotsky JM, et al. Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis. J Hepatol 2010; 52: 25-31.
15. Bronowicki JP, Hezode C, Bengtsson L et al. 100% SVT in IL28b CC patients treated with 12 weeks of telaprevir, peginterferon and ribavirin in the PROVE2 trial. J Hepatol 2012; 56 (Suppl 2 A): 430-431
16. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-50.
17. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2011; 376: 705-16.
18. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
19. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
20. Jacobson IM, Catlett I, Marcellin P, et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the advance trial. J Hepatol 2011; 54: S543.
21. Poordad F, Bronowicki JP, Gordon SC, et al. IL28B polymorphism predicts virological response in patients with hepatitis C genotype 1 treated with boceprevir combination therapy. J Hepatol 2011; 54: S6.
22. Deltenre P, Louvet A, Lemoine M, et al. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis. J Hepatol 2011; 55: 1187-94.
23. Serfaty L, Forns X, Tobias G et al. Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naïve patients infected with HCV genotype 1. Gut 2012; doi:10.1136/gutjnl-2011-300749 [Epub ahead of print].
24. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-24.
25. Bruno S, Vierling JM, Esteban R, et al. Boceprevir in addition to standard of care enhanced SVR in hepatitis C virus genotype-1 with advanced fibrosis/cirrhosis: subgroup analysis of SPRINT-2 and RESPOND-2 studies. J Hepatol 2011; 54: S4.
26. Poynard T, Colombo M, Bruix J, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009; 136: 1618-28.
27. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-303.
28. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
29. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
30. Vierling JM, Flamm SL, Gordon SC, et al. Efficacy of boceprevir in prior null responders tp Peg-interferon-Ribavirin: the PROVIDE study. Hepatology 2011; 54: A931.
31. Berg T, Andreone P, Pol S, et al. Predictors of virologic response with telaprevir-based combination treatment in HCV genotype 1-infected patients with prior peg-ifn/ribavirin failure: post-hoc analysis of the phase III REALIZE study. Hepatology 2011; 54: A32.
32. Pol S, Aerssens J, Zeuzem S, et al. Similar SVR rates in IL28B CC, CT or TT prior relapser, partial or null-responder patients treated with telaprevir/peg-IFN/ribavirin: retrospective analysis of the REALIZE study. J Hepatol 2011; 54: S6.
33. Bacon BR, Bruno S, Schiff ER, et al. Predictors of SVR among poor interferon responders when boceprevir is added to peg-interferon alfa 2b + ribavirin. Hepatology 2011; 54: A33.
34. Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011; 140: 459-68.
35. Lawitz E, Poordad F, Bronowicki JP, et al. The effect of using lower limit of quantitation (LLQ) versus lower limit of detection (LLD) for the definition of undetectable HCV RNA: data from the Respond-2 and Sprint-2 trials. Hepatology 2011; 54: A167.
36. Jacobson IM, Bartels DJ, Gritz L, et al. Futility rules in telaprevir combination treatment. J Hepatol 2012; 56: S24.
37. Gordon SC, Lawitz E, Bacon BR, et al. Adherence to assigned dosing regimen and sustained virologic response among hepatitis C genotype 1 treatment naïve and peg-ribavirin treatment-failures treated with boceprevir plus peg-IFN alfa 2b/ribavirin. J Hepatol 2011; 54: S173.
38. Sulkowski M, Poordad F, Manns MP, et al. Anemia during treatment with peginterferon alfa-2B/ribavirin with or without boceprevir is associated with higher SVR rates: analysis of previously untreated and previous-treatment-failure patients. J Hepatol 2011; 54: S194.
39. Reddy KR, Shiffman ML, Morgan TR, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007; 5: 124-9.
40. Sulkowski M, Reddy KR, Afdhal NH, et al. Anemia has no effect on efficacy outcomes in treatment-naive patients who received telaprevir-based regimen in ADVANCE and ILLUMINATE phase 3 studies. J Hepatol 2011; 54: S195.
41. Poordad FF, Lawitz EJ, Reddy KR et al. A randomized trial comparing ribavirin dose reduction versus erythropoietin for anemia management in previously untreated patients with chronic hepatitis C receiving boceprevir plus peginterferon/ribavirin. J Hepatol 2012; 56(Suppl 2): 55. A1419.